Feb 11, 2026 08:31AM
Feb 11, 2026 08:30AM
Feb 5, 2026 08:31AM
Feb 5, 2026 08:30AM
Jan 16, 2026 04:40PM
Jan 6, 2026 08:15AM
Jan 6, 2026 08:15AM Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
Dec 11, 2025 08:02AM
Dec 11, 2025 08:00AM
Dec 5, 2025 06:46AM
Dec 4, 2025 08:01AM
Dec 4, 2025 08:00AM
Nov 17, 2025 09:09AM
Nov 17, 2025 09:07AM Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
Nov 12, 2025 08:15AM
Oct 7, 2025 06:47AM
Oct 1, 2025 08:32AM
Oct 1, 2025 08:30AM
Sep 9, 2025 06:52AM
Sep 8, 2025 08:30AM
Sep 8, 2025 08:30AM Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
Aug 28, 2025 08:30AM
Aug 20, 2025 08:30AM
Aug 12, 2025 08:30AM
Jul 29, 2025 07:45AM
Jul 29, 2025 07:45AM
May 20, 2025 09:00AM
May 14, 2025 08:15AM Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen
May 13, 2025 08:00AM
Apr 30, 2025 08:45AM
Apr 30, 2025 08:45AM
Apr 29, 2025 08:47AM
Apr 29, 2025 08:45AM
Apr 22, 2025 08:45AM
Apr 22, 2025 08:45AM Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
Mar 26, 2025 06:52AM
Mar 25, 2025 08:00AM
Mar 11, 2025 08:15AM
Mar 11, 2025 08:15AM
Jan 30, 2025 08:17AM
Jan 30, 2025 08:17AM
Jan 23, 2025 08:15AM Atossa Therapeutics (ATOS) Issues Letter to Shareholders
Jan 23, 2025 08:15AM
Jan 6, 2025 09:00AM
Dec 12, 2024 08:15AM
Dec 11, 2024 08:15AM
Dec 11, 2024 08:15AM
Dec 10, 2024 09:05AM
Dec 9, 2024 08:15AM Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
Nov 21, 2024 08:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All